KOL Perspectives: Patient Niches in IBD

Summary

This KOL Insight briefing focuses on KOLs views of Patient Niches in IBD.

Questions topics -

• Perceptions on patient niches and treatments of fistulizing Crohn’s disease


• Perceptions on patient niches and treatments in small-bowel Crohn’s disease


• Perceptions on patient niches and treatments in pouchitis


• Perceptions on patient niches and treatments in acute severe UC

Key Highlights

• Most KOLs were unsure of the efficacy profile for JAK inhibitors in the treatment of fistulizing Crohn’s disease


• Most KOLs flagged the need for a targeted therapy that prevents long-term complications of SBCD


• Most KOLs noted that up to 50% of UC patients experience pouchitis after surgery, with antibiotics typically used before biologics.

Scope

• The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -

• 5 Europe-based & 5 N. America-based


• Interviews performed during July 2018

KOL data is analyzed to produce -

• Charts summarizing KOL opinions


• Chart call-outs of key information & details


• KOL quotes


• Summary of KOL reporting trends


• Insight from Sociable Pharma's analysts

Reasons to Buy

• Combines Qualitative & semi-quantitative insight from key opinion leaders on Patient Niches in IBD


• Includes insight & recommendations from our disease-specific healthcare analysts


• Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD


• Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.